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Abstract 
Background: Different countries have set different policies to control and decrease the costs of cardiovascular dis‑
eases (CVDs). Iran was aiming to reduce the economic burden of different disease by a recent reform from named as 
health transformation plan (HTP). This study aimed to examine the economic burden of CVDs before and after of HTP.
Methods: This cross‑sectional study was conducted on 600 patients with CVDs, who were randomly selected from a 
specialized cardiovascular hospital in the north‑west of Iran. Direct and indirect costs of CVDs were calculated using 
the cost of illness and human capital approaches. Data were collected using a researcher‑made checklist obtained 
from several sources including structured interviews, the Statistical Center of Iran, Iran’s Ministry of Cooperatives, 
Labor, and Social Welfare, the central bank of Iran, and the data of global burden of disease obtained from the Insti‑
tute for Health Metrics and Evaluation to estimate direct and mortality costs. All costs were calculated in Iranian Rials 
(IRR).
Results: Total costs of CVDs were about 5571 and 6700 billion IRR before and after the HTP, respectively. More than 
62% of the total costs of CVDs accounted for premature death before (64.89%) and after (62.01%) the HTP. The total 
hospitalization costs of CVDs was significantly increased after the HTP (p = 0.038). In both times, surgical services and 
visiting had the highest and lowest share of hospitalization costs, respectively. The OOP expenditure decreased signifi‑
cantly and reached from 54.2 to 36.7%. All hospitalization costs, except patients’ OOP expenditure, were significantly 
increased after the HTP about 1.3 times. Direct non‑medical costs reached from 2.4 to 3.3 billion before and after the 
HTP, respectively.
Conclusion: Economic burden of CVDs increased in the north‑west of Iran after the HTP due to the increase of all 
direct and indirect costs, except the OOP expenditure. Non‑allocation of defined resources, which coincided with the 
international and national political and economic challenges in Iran, led to unsustainable resources of the HTP. So, no 
results of this study can be attributed solely to the HTP. Therefore, more detailed studies should be carried out on the 
reasons for the significant increase in CVDs costs in the region.
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Background
Cardiovascular diseases (CVDs) are among the lead-
ing causes of death and the essential reason for prema-
ture death (before 65  years old). In 2017, CVDs were 
responsible for 17.7 million death around the world, 
which is around 31.8% of the total deaths in the world [1]. 
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Cardiovascular diseases are the cause of 161,000 deaths 
in Iran, which accounted for 45.45% of all deaths in the 
country in 2016. The age of CVDs has dropped and the 
incidence of CVDs among the population under 70 years 
has steepened during the last decade and reaching from 
569 in 2017 to 484 per 100,000 people [1, 2]. This trend 
for Europe had been estimated to be about 700 deaths 
among people under the age of 65  years in 2017 [3]. In 
Iran, this trend has also been tangible, and the rate of 
CVDs has been increased before the age of 60 years [4]. 
Increasing the rate of CVDs is one of the factors contrib-
uting to the increasing costs and economic burden of the 
disease [5]. Ardabil, one of the north-west provinces of 
Iran, has the highest rate of CVDs incidence and preva-
lence around the country. The proportion of deaths from 
CVDs was 2319 in 2015, accounting for 48.46% of all 
deaths in the province, which is higher than the world’s 
and Iran’s averages. The mortality rate of the disease in 
Ardabil had been estimated to be 180 cases per 100,000 
people in 2017 [6, 7].
Cardiovascular diseases costs are very high, so that in 
the European Union (EU) in 2016, the direct and indirect 
costs (premature death and disability) of CVDs were esti-
mated to be about 25 and 18 billion euros, respectively 
[3, 8]. It has also increased the inequality in health care 
financing by increasing OOP expenditure and cata-
strophic health expenditures [9]. In the US, the direct 
and indirect cost of CVDs was about 329.9 billion USD, 
and it is estimated to increase to 1.1 trillion USD in 2035 
[10]. The economic burden of CVDs in developing coun-
tries, such as Iran, which accounts for more than 75% of 
death rate, is more sever [11]. The economic burden of 
CVDs could have adverse effects on the country produc-
tivity and competitiveness, increase fiscal pressure on 
the health systems, and increase poverty, inequity, and 
opportunity loss in developing countries [12].
Different countries, especially low-income and devel-
oping countries, have implemented several reforms in 
their health system framework to prepare financial pro-
tection to patients by decreasing the economic burden 
of diseases [13, 14]. To this end, one of the most recent 
reforms in the Iranian health system, called the Health 
Transform Plan (HTP) with eight interventions for 
increasing equity in the health system, was implemented 
from early 2014 [15]. The central intervention of the HTP 
was reducing OOP expenditure for inpatient services 
in the hospitals affiliated with the Ministry of Health 
(MoHME) [15–17]. It also contains other interventions, 
such as encouraging physicians to stay in deprived areas 
and improving quality of care in the hospitals affiliated 
with MoHME through different interventions, such 
as increasing specialists, improving quality of outpa-
tient services of the attached polyclinics, and improving 
hospital amenities and lodging services [15, 18, 19]. These 
interventions have had different effects on patients’ sat-
isfaction and equity in the health system financing [19–
22]. The first intervention of the HTP aimed to decrease 
patients OOP expenditures as direct costs of the disease, 
and other interventions aimed to reduce indirect costs of 
disease through increasing access to health care services 
[18, 21].
Therefore, due to the high rate of CVDs in Iran, espe-
cially in Ardabil, as well as the implementation of the 
HTP as the essential equity-based intervention of the 
health system, this study was conducted to estimate the 
economic burden of CVDs before and after the HTP in 
the north-west of Iran.
Methods
This cross-sectional study was conducted during Sep-
tember 2019 to February 2020, to evaluate the eco-
nomic burden of CVDs in two periods: before (2013) 
and after (2016) the HTP implementation. The bottom-
up approach, the cost of disease, and the human capital 
approach (HCA) were used to calculate the total costs.
Study design and setting
This cross-sectional study was conducted before and 
after the HTP implementation in the north-west of Iran. 
A 550-bed cardiovascular specialized hospital affiliated 
with MoHME was selected as the study site. At both time 
points (before and after the HTP), data on direct, indi-
rect, and non-medical costs were collected from hospital-
based cardiovascular inpatients records and compared. 
Baseline data were collected from households with CVDs 
at two intervals.
Eligibility criteria
Patients with one of the CVDs (coronary artery steno-
sis, heart failure, heart attack, and cardiac rheumatism) 
in two periods, before (March 2012 to March 2013) and 
after (March 2016 to March 2017) the HTP, were eligible 
to participate in the study. Given that most hospitaliza-
tion costs occur in the early years of the diagnosis and 
treatment of CVDs, the diagnosis of the disease over the 
past year was the basis of inclusion.
Sampling methodology and sample size
Samples were collected from a specialized cardiovas-
cular hospital the most extensive and only reference for 
patients with CVDs using a purposive random sampling 
method. Initially, a list of all patients admitted to the 
study during the two intervals was prepared, and data 
were collected from inpatients medical records through 
a checklist. If necessary, patients who were eligible to 
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participate in the study were contacted, and additional 
information was obtained via telephone interview.
Four types of CVDs with high frequency (coronary 
artery stenosis, heart failure, heart attack, and cardiac 
rheumatism) were selected to estimate sample size. Then, 
the medical records of 40 discharged patients were ran-
domly selected and evaluated for cost. Based on the 
mean and variance of hospital costs and using Cohen’s 
sampling method, the sample size was estimated to be 
253 (n = 800) before and 284 (n = 1300) after the HTP.
Cohen’s d is simply a measure of the distance between 
two means, measured in standard deviations [23]. It is 
calculated using Eq. (1):
where M1 and M2 are the means for the 1st and 2nd sam-
ples, and SDpooled is the pooled standard deviation for the 
samples. SDpooled is appropriately calculated using the fol-
lowing equation:
Accordingly, the total number of hospitalizations for 
CVDs was extracted from the hospital information sys-
tem (HIS), then, 600 patients for both intervals (300 
before and 300 after the HTP) were randomly selected 
using random number table.
A pilot study was conducted a month before (August 
2019) on 30 inpatients with CVDs by a face-to-face inter-
view to estimate indirect costs in the last month. The data 
were extracted using a checklist. Data were multiplied 
by 12 to estimate the total costs in the last year. Based 
on the mean and variance of hospital costs and using 
Cohen’s sampling method, the sample size was estimated 
to be 180 for both time points, before and after the HTP 
implementation. By telephone follow-up, patients were 
selected from the direct costs calculation phase (n = 300). 
Contact with all selected patients continued until the 
designated sample size was obtained.
Data collection
Data were collected using a researcher-made checklist 
included age, sex, length of hospital stay, hospitalization 
costs, and other related costs (visitation, diagnostic ser-
vices, hoteling expense (bed-days expense), surgery, and 
medication), which were extracted from the patients’ 
medical records. A checklist used in other similar inter-
national studies was used to collect non-hospital and 
non-medical costs [24, 25]. The questionnaire consisted 
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information (age, gender, marital status, education sta-
tus, and the number of family members), duration of ill-
ness, and insurance information. Also, the second section 
included information on indirect costs (absenteeism, sick 
leave, disability, etc.).
Study variables and data sources
In this study, multiple data sources were used to estimate 
the economic burden of the disease. The most important 
data source used to estimate direct medical costs were 
the information extracted from the medical records of 
the patients with CVDs.
Direct costs
This type of costs is directly attributable to patients 
admitted to various types of health care facilities (Minis-
try of Health, Social Security, and private sector), as well 
as treatment costs, including different services, such as 
diagnostic, medical, and rehabilitation services [26]. To 
estimate direct costs, the costs of standard diagnostic 
services, such as electrocardiograms, echocardiography, 
exercise testing, nuclear heart scan, and angiography, 
were included. Sampling was performed among patients 
who had undergone open-heart surgery, angioplasty, and 
medication. Sample sizes for the three groups (under-
gone open-heart surgery, angioplasty, and medication) 
were 135, 251, and 221 people, respectively. Sampling 
was performed using simple random sampling method 
and Cochrane-Orcutt Procedure, which is applicable for 
a limited population, was used. The main drugs for CVDs 
were also extracted by reviewing 65 patients’ medical 
records and interviews with CVDs specialists. In this sec-
tion, direct payments were considered as the patients’ 
OOP expenditure, which can be due to the difference 
between the patient’s share of the cost and share of the 
insurance cost, which was recorded as the patient’s share 
of the costs in their medical record.
Indirect costs
Indirect costs are a combination of the costs incurred to 
the patients and their families, such as the cost of medical 
travel, cost of time lost, and cost of patient in-home care 
[27].
Time costs
Time costs are calculated based on the mean number of 
days lost due to receiving health care services and hos-
pitalization in the hospital. In this study, time costs were 
calculated by multiplying the number of hospitalization 
days by the average daily wage. Data for an average daily 
wage were obtained from the report of the Ministry of 
Cooperatives, Labor, and Social Welfare of Iran in 2018.
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Premature death costs
The human capital approach was used as the primary 
method for the estimation of premature death costs in 
this study. In previous studies, HCA was used for the 
estimation of premature death due to non-communica-
ble diseases, such as CVDs [28, 29]. Total numbers of 
deaths due to CVDs during last 5 years were obtained 
from documents of the hospital and deputy of the 
health of ARUMS. The data adopted to the data of the 
Institute for Health Metrics and Evaluation (IHME) and 
Global Burden of Disease (GBD), and then, registered.
Data sources and manipulation
Data were collected using structured interviews with 
patients, medical records, and valid data sources.
• Population, employment rate, and life expectancy 
were extracted from the latest report provided by 
the Iranian Statistic Center (ISC).
• CVDs morbidity and mortality data were extracted 
from the National and Subnational Burden of Dis-
eases, Injuries, and Risk Factors (NASBAD) survey.
• The final report by the Central Bank of the Islamic 
Republic of Iran was used to identify and determine 
the exchange rate by year.
• The average daily cost (the daily minimum wage 
lost) was calculated according to the principles pre-
sented by the Ministry of Cooperatives, Labor, and 
Social Welfare of Iran.
• The difference between payments by patients 
(patient’s share) and the insurance liability was cal-
culated to determine the OOP expenditure.
• Indirect costs identified by data extracting through 
interviews with patients and their relatives who 
were aware of patients’ diseases using the designed 
checklist.
• Given that, there were no precise statistics on the 
level of household income, their income was esti-
mated based on the minimum declared incomes 
of the Ministry of Labor, Cooperatives and Social 
Welfare.
• Other information, such as disease incidence, occu-
pancy rate, payroll, GDP, national health expen-
ditures, and standardized life expectancy were 
extracted from previous studies, treatment guide-
lines, World Bank databases, Iranian Ministry of 
Health (MoHME), and Iranian Statistic Center 
(ISC).
• All costs were equalled and presented in Iranian 
Rials (IRR) in two periods (the average exchange rate 
in 2013 equals 1$ = 31,840 IRR and in 2016 equals 
1$ = 36,429 IRR).
Data analysis
The human capital approach considers the valuation 
of waste resulting from premature death for the whole 
economy [30]. Individuals play an economic role in 
society by generating, earning, and consuming. Thus, 
by calculating production, income, or consumption, the 
extent of the impact of one’s economic activities can be 
estimated.
In the present study, the discount rate of 3% was used 
to obtain the present value of the lost production. The 
Present Discounted Value of Lifetime Earnings (PVLE) 
model developed by Max et  al. (2000) was also used to 
calculate and estimate the present value of the patients’ 
income [31].
Data were analyzed using SPSS version 16 (SPSS Inc., 
Chicago, IL, USA) [32] and Excel software version 2013. 
Continuous variables are reported as means ± standard 
deviation. Categorical variables are reported as propor-
tions (%). Continuous variables were compared using 
t-test and one-way ANOVA, and categorical variables 
were compared using the Chi-square test.
Results
The prevalence of CVDs in Ardabil before and after the 
HTP was 44.12% and 50.11%, respectively. The number of 
deaths due to CVDs in Ardabil before and after the HTP 
was 2627 and 2940, respectively that accounts for 42.3% 
and 45.4% of the total deaths in the province, respectively.
Demographic status
The results showed that 68.8% and 65.3% of the par-
ticipants were men before and after the HTP, respec-
tively. The mean age of patients in the two intervals was 
62.4 ± 9.2 and 62.6 ± 8.6  years, respectively. The mini-
mum and maximum hospital stay were one to 11  days, 
while the mean length of hospitalization in the two 
periods (before and after the HTP) was 1.5 ± 1.3 and 
1.5 ± 3.9 days, respectively (Table 1).
Hospitalization costs
Data were extracted from the medical record of patients 
to estimate the hospitalization costs. The average cost of 
hospitalization per patient was 2.96 ± 4.18 million IRR, 
which was 3.69 and 4.64 million IRR before and after the 
HTP, respectively. The average daily cost of hospitaliza-
tion before and after the HTP was 1.04 and 1.28 million 
IRR, respectively, and the total daily cost of hospitaliza-
tion was 3.06 ± 1.10 million IRR. The total cost of hos-
pitalization before and after the HTP was 6.51 and 8.47 
billion IRR, respectively, indicating that it was increased 
about 1.3 times more. The distribution of direct 
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hospitalization costs in patients with CVDs by service 
type is presented in Table 2.
Based on the total number of patients with CVDs iden-
tified and the average cost of hospitalization over the two 
time periods, the total cost of hospitalization of patients 
with CVDs in the two time periods was estimated to be 
1953 and 2541 billion IRR, respectively. Most of the hos-
pitalization costs in both periods were related to surgi-
cal services (59.4% and 56.8%) and medication (18.3% 
and 19.1%). The ratio of indirect costs to the total hos-
pitalization costs was reduced by 33%. In terms of all 
costs associated with providing services to patients with 
CVDs, except OOP expenditure, there was an increase in 
the costs after the HTP, while the highest rate belonged 
to the cost of open-heart surgery and the lowest one was 
related to angioplasty and angiography (Fig. 1).
Non‑medical direct costs (lost time costs)
In the present study, the patients’ direct non-medi-
cal costs (time and travel costs) were identified and 
calculated by telephone interviews with the patients 
before and after the HTP.
Before and after the HTP, 60.6% and 57.1% of the 
patients were employed (self-employed, government 
employee, and retired persons) and others were unem-
ployed (unemployed, housewife), respectively. The mean 
total days lost due to the diseases for both groups of 
patients (employed and unemployed) were estimated to 
be 61  days (17  days due to medical travel and 44  days 
due to disability). The average cost per patient per day 
was calculated based on the mean income. For this pur-
pose, the average monthly income of employed persons 
was calculated and divided into 30  days, and one-day 
income was calculated, which was 0.28 and 0.33 million 
IRR before and after the HTP. The average daily cost of 
unemployed patients was also calculated based on the 
minimum wage, which was declared by the Ministry of 
Cooperatives, Labor, and Social Welfare in the two time 
periods. Accordingly, the average daily cost of unem-
ployed patients (minimum wage lost daily) was estimated 
to be 0.16 and 0.27 million IRR before and after the HTP.
The total cost of time lost due to medical travelling by 
employed patients was estimated to be 4.80 and 5.63 mil-
lion IRR before and after the HTP. The total cost of time 
lost due to disability was estimated to be 12.42 and 14.59 
million IRR before and after the HTP. The total cost of 
travel and disability of employed patients before and after 
the HTP was 1.87 and 2.08 billion IRR, respectively, and 
for unemployed patients, it was estimated to be 541.94 
and 734.35 million IRR before and after the HTP, respec-
tively. The average cost of time lost due to medical travel 
of unemployed patients was 2.76 and 4.60 million IRR 
before and after the HTP, respectively. The cost of time 
lost due to disability in the two time periods was esti-
mated at 7.14 and 11.91 million IRR, respectively. The 
total cost of time lost for the unemployed patients was 
Table 1 Baseline demographic characteristics of  patients 
with CVD before and after HTP in north-west of Iran
Demographic characteristics Before HTP After HTP P‑value
Total subjects 300 300
Age mean (years) 62.43 62.61 0.881
Age groups, % 0.865
 < 35 3.73 3.84
 35–44 6.08 6.07
 45–54 13.48 13.49
 55–64 26.34 26.33
 65 + 50.37 50.27
Gender 0.224
 Male 68.6 65.3
Average length of stay (ALOS) 3.42 3.88 0.702
Table 2 Average and total cost of hospitalization for patients with cardiovascular disease in Ardabil (North-west of Iran), 
2018
HTP  health transformation plan, OOP  out of pocket, Prec.change  percentage of change
a Refers to the inpatient’s overhead cost for the bed, patients companion and the cost of food and other non-medical expenses
Service item Before HTP After HTP Prec. change P‑value
Mean cost Total cost Total cost (%) Mean cost Total cost Total cost (%)
Diagnostic tests 4,902,546 1,416,345,612 13.3 6,733,684 1,935,260,657 14.5 1.37 0.000
Medication and drugs 6,745,609 2,005,469,481 18.3 8,869,887 2,613,068,600 19.1 1.30 0.000
Surgical services
Open surgery 14,080,998 1,824,897,276 38.2 15,185,617 2,154,839,112 32.7 1.18 0.000
Angiography/angioplasty 7,814,585 307,113,191 21.2 11,191,846 496,917,984 24.1 1.62 0.000
Visiting 1,142,699 342,809,625 3.1 1,486,054 445,816,291 3.2 1.30 0.000
Hoteling  expencea 2,248,536 614,524,957 6.1 2,972,109 826,543,404 6.4 1.35 0.000
OOP as a proportion of household total expenditure 54.2 36.7 0.67 0.000
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estimated to be 0.526 and 1.27 billion IRR before and 
after the HTP, respectively.
Indirect cost (premature death and disability)
Indirect costs were estimated in terms of prema-
ture death and mean life expectancy for both sexes 
(75.15  years in 2013 and 75.95 in 2016). In Arda-
bil province, 880 people with ages of 35 to 75  years 
died due to CVDs in 2013, which was reduced to 782 
in 2016. The total cost of premature death costs was 
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Fig. 1 a Main component of cardiovascular disease cost in North‑West of Iran before and after HTP. b Hospitalization costs of cardiovascular 
diseases (CVDs), before and after of health transformation plan (HTP). Values are presented as mean and standard deviation (SD). Based on 
estimation there were significant difference between diagnostic tests (DT) *p < 0.001, medication & drugs (M & D) **p < 0.001, open surgery (OS) 
***p < 0.001, angiography/angioplasty (An) #p < 0.001, visiting (Vis) ##p < 0.001, and hoteling expense (HoT) ###p < 0.001 before and after of HTP in 
CVDs
Table 3 Total cost of cardiovascular disease in North-West of Iran (Ardabil), 2013–2016
Service item Mean cost Total cost (%) p‑value
Before HTP After HTP Before HTP After HTP
Hospitalization 1,953,348,042,488 2,541,733,814,194 35.06 37.93 0.038
Direct non‑medical of cost 2,404,333,500 3,355,790,560 0.04 0.05 0.041
Mortality cost 3,615,314,347,567 4,155,499,500,311 64.89 62.01 0.081
Total cost 5,571,066,723,555 6,700,589,105,065 100 100 0.047
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Total economic burden of CVDs
The total cost of CVDs in the north-west of Iran (Arda-
bil) before and after the HTP was 5571.06 and 6700.58 
billion IRR, respectively. Overall, the results showed a 
significant difference in the hospitalization and indirect 
costs (medical travel and disability costs) of patients 
before and after the HTP (P < 0.05). However, despite the 
relative increase, the indirect and indirect mortality costs 
were not significantly different (P < 0.05).
Discussion
Cardiovascular diseases (CVDs) are among costly dis-
eases for patients, their families, and health systems 
around the world. Different health systems trying to con-
trol and decrease the costs of CVDs by different reforms 
and restructures with a non-communicable disease con-
trol approach [33]. Health transformation plan (HTP) 
is the main reform in Iran’s health system toward the 
development of health care equity in the country [15, 22]. 
One of the main objectives of the HTP was providing fair 
financing and accessibility to the health care services [16, 
22], which was expected to reduce the economic burden 
on Iran’s health system. The prevalence of CVDs in Iran 
was 179 and 194 per 100,000 people before and after the 
HTP, respectively [1].
This study aimed to evaluate the economic burden of 
CVDs in the north-west of Iran, an area with the high-
est incidence and prevalence of CVDs [5], before and 
after the HTP to identify the impact of the plan on the 
CVDs’ economic burden indexes. Based on the results 
of the present study, the total economic costs of CVDs 
were estimated 5,571,066,723,555 and 6,700,589,105,065 
IR before and after the HTP, respectively. It shows that 
the total costs of CVDs significantly increased about 1.2 
times after the HTP and caused more inequitable status 
for patients with CVDs in the health system of Iran. This 
finding is inconsistent with the findings of other stud-
ies, where a qualitative study in Iran concluded that the 
HTP in all dimensions has reduced costs and justified the 
health system [22]. The finding is inconsistent with the 
results of a study by Chapman et  al. (2011), where they 
claimed that inpatient costs of CVDs over time were 
decreased [34]. The difference between the findings of 
the present study and those of Chapman et al. (2011) may 
be due to the difference in the context of the studies and 
methodology.
This study showed that mortality cost is one of the 
main components of CVDs economic burden in the 
north-west of Iran in both periods (before and after the 
HTP) so that more than 62% of the total costs of CVDs 
can be attributed to the mortality costs. The study also 
showed that despite a reduction in the percentage of the 
CVDs mortality cost after the HTP, this reduction was 
not statistically significant compared to that before the 
HTP, which is not consistent with the findings of most 
studies in developed countries. In European countries, 
more than 60% of the total costs of CVDs attributed 
to the hospitalization [35, 36], while in other studies, it 
was reported that just about 23% of CVDs costs attrib-
uted to the mortality costs in the UK [24] and about 33% 
in South Korea [37]. One of the reasons for this may be 
due to the low mean age of CVDs mortality and morbid-
ity in developing countries, such as Iran [38]. In 2017, 
the mortality rate of CVDs in Iran and countries with 
high socio-economic indexes was about 271 and 125 per 
100,000 people per year, respectively [1]. A cohort-based 
study in Iran (2013), showed that CVDs mortality rate in 
men and women was 331 and 203 per 100,000 people per 
year, which is almost two times higher than the average 
income of countries [39]. These pieces of evidence sug-
gest that premature mortality and morbidity increased 
the proportion of mortality costs compared to the other 
costs of CVDs in the north-west of Iran. Besides, it is 
worth mentioning that the costs of health service in Iran 
are lower than those in developed countries and some 
other Middle Eastern countries [26, 40], and this can lead 
to a lower proportion of hospitalization costs to the total 
CVDs costs in Iran.
Furthermore, it was revealed that surgical services 
accounted for the highest proportion of costs compared 
to the other components of hospitalization costs before 
and after the HTP, which means that the total costs of 
open surgery and angiography/angioplasty increased 
more than other hospitalization costs after the HTP. In 
the UK, hospital inpatient care was estimated about 63% 
of the total CVDs costs, and surgical services were intro-
duced as the largest share of hospitalization costs [24], 
which confirms the results of the present study. Another 
study in Serbia showed that more than 60% of the costs 
are attributed to hospitalization and surgical services, 
which is consistent with the results of the present study 
[36]. Similarly, another study on patients with CVDs in 
Iran reported direct care costs as a significant propor-
tion of the costs associated with open-heart surgery costs 
[41].
The proportion of hospitalization costs have been 
increased significantly after the HTP. One of the leading 
causes of this increase could be increasing hospitalization 
rate after the HTP. Karami et al. (2017) reported that the 
hospitalization rate was increased after the HTP in Iran 
[42]. Tabari-Khomeiran (2019) also showed that CVDs 
hospitalization costs increased significantly after the 
HTP [21]. After the implementation of the HTP, access 
to health services and responsiveness have been signifi-
cantly increased, and as a result, health care expenditures 
in Iran have also been increased [18, 43].
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The main objective of the first phase of the HTP was 
decreasing OOP expenditures of inpatients based on 
the patients’ insurance type (rural or urban) by allocat-
ing subsidies to increase the share of government health 
expenditures [15, 16, 44, 45]. However, the results of the 
present study showed that the mean total hospitaliza-
tion costs after the HTP implementation have increased 
by 20%. However, OOP expenditures decreased by 
about 30% after the HTP for CVDs in this study. 
According to various studies, the share of OOP expen-
ditures has declined by an average of 20% after the HTP, 
from about 58% to 37% [20, 21]. After the implemen-
tation of the HTP in Turkey, patients OOP and their 
financial share of health system decreased [46]. Accord-
ingly, it can be concluded that despite the decrease in 
the OOP expenditures and patient’s share of health 
service payment due to the HTP, the economic burden 
of CVDs increased. This increase can be due to several 
reasons, including:
• Increasing hospitalization rate and the average length 
of stay: the increase of the average length of stay can 
be due to the increase of patients satisfaction and 
decrease of personal discharge rate [47].
• Lack of initiatives, such as failure to fully implement 
the referral system, and increasing referrals to spe-
cialized levels of health care system led to system fail-
ure to achieve Universal Health Coverage (UHC) [48, 
49].
• Lack of timely and appropriate allocation of defined 
resources after the HTP caused a failure to fully 
adhere to the HTP guidelines [18, 50].
• The increase of outpatient OOP, where Rad et  al. 
(2017) reported a significant increase of OOP pay-
ments for outpatient care services increased after 
the HTP, which influenced the total OOP [19]. Also, 
despite the increase in the share of health from GDP 
after the HTP in Iran, catastrophic and impoverish-
ment expenditures have not decreased sufficiently to 
achieve the goals of the HTP in term of the financial 
risk protection [51].
• Failure to fully implement the HTP and its related 
laws, as Sajadi et al. (2019) reported that unsustain-
able resource allocation is one of the main challenges 
of Iran’s health system before and after the HTP [52]. 
This has led to the failure of most of the formulated 
policies to achieve their goals on the path to UHC.
• Finally in developing countries, the increase of 
the costs of health care services with a decrease of 
patients OOP expenditures can mean the provision 
of the costs to the public budgets, which can be inter-
preted as an increase in the government subsidies to 
the health sector [16]. Therefore, it can be claimed 
that the Iranian government has increased the health 
system subsidies by shifting resources from target-
ing subsidies and one per cent value-added tax to the 
health system, which is confirmed by similar studies 
[53, 54].
However, this study had several strengths and limita-
tions related to the study design and costs measurement. 
First, a province from the north-west of Iran (Ardabil), 
which has the highest level of CVDs, was selected, and 
the economic burden of CVDs that has not been studied 
before, was investigated. In addition, this study, for the 
first time, investigated the HTP and its effect on the eco-
nomic burden of CVDs in Iran. In this regard, the evalua-
tion of the economic burden of CVDs before and after the 
implementation of the main reform in Iran’s health sec-
tor, which may help policy makers to reorder the existing 
policies incorporated in the HTP in terms of affordabil-
ity of the use of valid databases and robust methods with 
acceptable sample size to identify and capture the expen-
ditures, is another strength of this study. Classification of 
the costs into three groups in general, non-calculation of 
outpatient costs and informal payments, and the possibil-
ity of recall bias in the patients during the study period, 
especially regarding indirect and non-medical costs, and 
excluding some demographic data because of high rate of 
missing can be considered as the main limitations of the 
present study.
Conclusion
According to the results, after the implementation of the 
HTP in Iran, the economic burden of CVDs increased sig-
nificantly (about 1.2 times), especially in the mortality costs 
and inpatient surgical services costs. Therefore, it can be 
concluded that the HTP, despite the decline in OOP expen-
ditures and patients’ share of the total health expenditures, 
the economic burdens on the health system because of sev-
eral reasons, including failure to fully implement the refer-
ral system and increased referrals to the specialized levels 
of the health system, increased while the OOP expendi-
tures decreased. As a result, the total costs of the health 
system increased and imposed pressure on the country’s 
general budget. Finally, based on the HTP objectives in 
terms of equity in health care financing and the results of 
this study, it can be concluded that the costs of CVDs in 
Iran are significantly high. The HTP has not touched its all 
goals about CVDs costs. It could be because of the non-
allocation of financial resources defined to the HTP, one 
per cent value-added tax, and 10% of targeted subsidies, 
after the implementation of the plan, as well as the political 
and economic challenges occurred during the years follow-
ing the HTP implementation in Iran. Further studies are 
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needed to find ways to modify the challenges and reduce 
the economic burden of CVDs by the HTP in Iran.
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